DEA now allows pharmacies to deliver controlled substances to a practitioner’s office under a patient power of attorney. What ...

APC’s committees shape our policy positions, build educational programming, and make member services stronger. The Pharmacy Compounding Foundation, APC’s charitable arm, has its own committees too.

Congratulations to the five newly elected or reelected members of APC's Board of Directors for 2027. Beginning January 1, 2027, they'll join their fellow board members in setting APC's direction, ...

FDA Agency IQ reports that a new telehealth venture has been cited by FDA for marketing a compounded GLP-1 in chocolate form, using orforglipron – the active ingredient in an FDA-approved drug ...

On Tuesday, APC met with the White House Office of Information and Regulatory Affairs to make the case for allowing compounding of six peptides under a framework that includes essential patient-safety ...

Register for APC’s November 19 webinar with pharmacy tax specialist Scotty Sykes, CPA, CFP — covering multistate tax considerations, R&D tax credits, buy-sell planning, and other opportunities ...

This week the New Jersey Assembly Health Committee held a nearly three-hour hearing on the safety, affordability, and accessibility of GLP-1 medications. The committee heard from industry, physicians, ...

Something is definitely stirring on the peptide front. A new entry on the federal government’s regulatory review website indicates that FDA has submitted an action titled “Interim Access Policy for ...

A wide-ranging conversation on the Hims House podcast looks at where peptides stand today, including the rumors, the regulatory uncertainty, the real concerns, and the road ahead. APC CEO Scott ...

In a LinkedIn post this week, our CEO discussed reports that pharmacies are being pressured to accept board penalties rather than contest them, undermining the fair process licensees are owed.